27294781|t|N-linked glycosylation of SV2 is required for binding and uptake of botulinum neurotoxin A
27294781|a|Botulinum neurotoxin serotype A1 (BoNT/A1), a licensed drug widely used for medical and cosmetic applications, exerts its action by invading motoneurons. Here we report a 2.0-Ã…-resolution crystal structure of the BoNT/A1 receptor - binding domain in complex with its neuronal receptor, glycosylated human SV2C. We found that the neuronal tropism of BoNT/A1 requires recognition of both the peptide moiety and an N-linked glycan on SV2. This N-glycan -which is conserved in all SV2 isoforms across vertebrates -is essential for BoNT/A1 binding to neurons and for its potent neurotoxicity. The glycan - binding interface on SV2 is targeted by a human BoNT/A1 - neutralizing antibody currently licensed as an antibotulism drug. Our studies reveal a new paradigm of host-pathogen interactions, in which pathogens exploit conserved host post-translational modifications, thereby achieving highly specific receptor binding while also tolerating genetic changes across multiple isoforms of receptors.
27294781	0	22	N-linked glycosylation	T044	C0376322
27294781	26	29	SV2	T116,T123	C3711414
27294781	46	53	binding	T044	C0033618
27294781	58	64	uptake	T039	C0243144
27294781	68	90	botulinum neurotoxin A	T116,T121,T131	C0006050
27294781	91	123	Botulinum neurotoxin serotype A1	T116,T121,T131	C0006050
27294781	125	132	BoNT/A1	T116,T121,T131	C0006050
27294781	137	145	licensed	T089	C0023636
27294781	146	150	drug	T121	C1254351
27294781	167	174	medical	T121	C0013227
27294781	179	200	cosmetic applications	T073	C0010164
27294781	232	243	motoneurons	T025	C0026609
27294781	279	296	crystal structure	T104	C0444626
27294781	304	320	BoNT/A1 receptor	T116,T121,T131	C0006050
27294781	323	337	binding domain	T087	C1514535
27294781	341	348	complex	T104	C1704241
27294781	358	375	neuronal receptor	T026	C2325760
27294781	377	389	glycosylated	T044	C0376322
27294781	390	400	human SV2C	T116,T123	C3711414
27294781	420	428	neuronal	T129	C0521390
27294781	429	436	tropism	T039	C1328821
27294781	440	447	BoNT/A1	T116,T121,T131	C0006050
27294781	457	468	recognition	T044	C0599844
27294781	481	495	peptide moiety	T116	C0030956
27294781	503	518	N-linked glycan	T109,T121	C0032594
27294781	522	525	SV2	T116,T123	C3711414
27294781	532	540	N-glycan	T109,T121	C0032594
27294781	568	571	SV2	T116,T123	C3711414
27294781	572	580	isoforms	T116	C0597298
27294781	588	599	vertebrates	T010	C0042567
27294781	618	625	BoNT/A1	T116,T121,T131	C0006050
27294781	626	633	binding	T044	C0033618
27294781	637	644	neurons	T025	C0027882
27294781	664	677	neurotoxicity	T037	C0235032
27294781	683	689	glycan	T109,T121	C0032594
27294781	692	699	binding	T044	C0033618
27294781	713	716	SV2	T116,T123	C3711414
27294781	720	728	targeted	T169	C1521840
27294781	734	739	human	T016	C0086418
27294781	740	747	BoNT/A1	T116,T121,T131	C0006050
27294781	750	771	neutralizing antibody	T116,T129	C0475463
27294781	782	790	licensed	T089	C0023636
27294781	797	814	antibotulism drug	T121	C1254351
27294781	841	849	paradigm	T062	C0681797
27294781	853	879	host-pathogen interactions	T040	C1752856
27294781	890	899	pathogens	T001	C0450254
27294781	918	922	host	T001	C1167395
27294781	923	955	post-translational modifications	T044	C0033666
27294781	991	1007	receptor binding	T044	C0597358
27294781	1030	1045	genetic changes	T049	C1705285
27294781	1062	1070	isoforms	T116	C0597298
27294781	1074	1083	receptors	T116,T192	C0597357